With a big stake in hand, Samantha Du files for $115M IPO for Zai Lab
In three years Shanghai-based Zai Lab has in-licensed a pipeline of 6 clinical-stage therapeutics from a group of small and large global players, moved to the start of its first Phase III trial and built out its first manufacturing facility — with a bigger operation on the drawing board.
Now the execs at Zai Lab want to raise around $115 million in a US IPO to keep the gas pedal pressed to the floor as the biotech, led by Samantha Du, continues to charge ahead on three key disease fronts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.